2026 Commercial Insurance Innovative Drug List
Complete 28-drug directory published Nov 14, 2026 (effective Jan 1, 2027), audited against the 19-drug 2025 baseline edition: 12 newly added, 1 indication expanded, 15 retained, and 3 removed from the 2025 list (2 graduated into basic NRDL).
Policy scope note: Inclusion in the NHSA Commercial Health Insurance Innovative Drug List indicates national catalog listing for commercial insurer reference (basic medical insurance funds do not reimburse these drugs). Actual patient reimbursement depends on individual commercial health insurance policy contracts.
Complete 2026 Directory (28 drugs)
| No. & Brand | Generic Name | MAH & Authorized Entity | Listed Indication Scope | Validity & Status | Source |
|---|---|---|---|---|---|
#1 戈芮宁 Retained from 2025 | Velaglucerase beta for Injection 注射用维拉苷酶β | 北海康成(上海)生物科技有限公司 | Long-term enzyme replacement therapy (ERT) for adolescents ≥12y and adults with type I and type III Gaucher disease. | Jan 1, 2026 – Dec 31, 2027 Effective | NHSA · PDF p.2 Verified 2026-11-21 |
#2 Revestive / 瑞唯抒 Retained from 2025 | Teduglutide for Injection 注射用替度格鲁肽 | Takeda Pharmaceuticals International AG Ireland Branch Authorized: 武田(中国)国际贸易有限公司 | Short bowel syndrome (SBS) in adults and children ≥1y who are stable following intestinal adaptation and dependent on parenteral support. | Jan 1, 2026 – Dec 31, 2027 Effective | NHSA · PDF p.2 Verified 2026-11-21 |
#3 Cablivi / 可倍力 Added 2026 | Caplacizumab for Injection 注射用卡拉西珠单抗 | Ablynx NV Authorized: 赛诺菲(中国)投资有限公司上海分公司 | Acquired thrombotic thrombocytopenic purpura (aTTP/iTTP) in adults and adolescents ≥12y (≥40 kg) combined with plasma exchange and immunosuppression. | Jan 1, 2027 – Dec 31, 2028 Announced · Effective Jan 1, 2027 | NHSA · PDF p.2 Verified 2026-11-21 |
#4 信玖凝 Added 2026 | Dalnacogene ponparvovec Injection 波哌达可基注射液 | 上海信致医药科技有限公司 | Moderate-to-severe hemophilia B (congenital Factor IX deficiency) in adult patients. | Jan 1, 2027 – Dec 31, 2028 Announced · Effective Jan 1, 2027 | NHSA · PDF p.2 Verified 2026-11-21 |
#5 Ziihera / 百赫安 Retained from 2025 | Zanidatamab for Injection 注射用泽尼达妥单抗 | 百济神州(苏州)生物科技有限公司 Authorized: 百济神州(北京)生物科技有限公司 | Previously treated HER2-high (IHC 3+) unresectable locally advanced or metastatic biliary tract cancer. | Jan 1, 2026 – Dec 31, 2027 Effective | NHSA · PDF p.2 Verified 2026-11-21 |
#6 Elrexfio / 易瑞欧 Retained from 2025 | Elranatamab Injection 埃纳妥单抗注射液 | Pfizer Inc. Authorized: 辉瑞投资有限公司 | Adult relapsed or refractory multiple myeloma after ≥3 prior lines (including a PI, IMiD, and anti-CD38 mAb). | Jan 1, 2026 – Dec 31, 2027 Effective | NHSA · PDF p.2 Verified 2026-11-21 |
#7 Qarziba / 凯泽百 Retained from 2025 | Dinutuximab beta Injection 达妥昔单抗β注射液 | Recordati Netherlands B.V. Authorized: 百济神州(北京)生物科技有限公司 | High-risk neuroblastoma in patients ≥12 months after induction chemo + myeloablative therapy/SCT, or relapsed/refractory neuroblastoma. | Jan 1, 2026 – Dec 31, 2027 Effective | NHSA · PDF p.2 Verified 2026-11-21 |
#8 Danyelza / 达佑泽 Retained from 2025 | Naxitamab Injection 那西妥单抗注射液 | Y-mAbs Therapeutics, Inc. Authorized: 赛生医药江苏有限公司 | Relapsed/refractory high-risk neuroblastoma in bone or bone marrow (children ≥1y and adults) in combination with GM-CSF. | Jan 1, 2026 – Dec 31, 2027 Effective | NHSA · PDF p.3 Verified 2026-11-21 |
#9 Talvey / 拓立珂 Retained from 2025 | Talquetamab Injection 塔奎妥单抗注射液 | Janssen-Cilag International NV Authorized: 强生制药有限公司 | Monotherapy for adult relapsed or refractory multiple myeloma after ≥3 prior lines (PI, IMiD, and anti-CD38 antibody). | Jan 1, 2026 – Dec 31, 2027 Effective | NHSA · PDF p.3 Verified 2026-11-21 |
#10 Yervoy / 逸沃 Retained from 2025 | Ipilimumab Injection 伊匹木单抗注射液 | Bristol-Myers Squibb Pharma EEIG Authorized: 百时美施贵宝(中国)投资有限公司 | In combination with nivolumab: (1) 1L unresectable non-epithelioid MPM; (2) 1L unresectable/metastatic MSI-H/dMMR CRC; (3) 1L unresectable/advanced HCC. | Jan 1, 2026 – Dec 31, 2027 Effective | NHSA · PDF p.3 Verified 2026-11-21 |
#11 Poteligeo / 惠尔金 Added 2026 | Mogamulizumab Injection 莫格利珠单抗注射液 | Kyowa Kirin Co.,Ltd. Authorized: 维健(中国)制药有限公司 | Adult relapsed or refractory Sézary syndrome (SS) or advanced (stage III/IV) mycosis fungoides (MF) after prior systemic therapy. | Jan 1, 2027 – Dec 31, 2028 Announced · Effective Jan 1, 2027 | NHSA · PDF p.3 Verified 2026-11-21 |
#12 Yescarta / 奕凯达 Retained from 2025 | Axicabtagene ciloleucel Injection 阿基仑赛注射液 | 复星凯瑞(上海)生物科技有限公司 | CD19 CAR-T for adult r/r LBCL refractory to or relapsed ≤12 months after 1L immunochemotherapy (conditional), and ≥3L adult r/r LBCL. | Jan 1, 2026 – Dec 31, 2027 Effective | NHSA · PDF p.3 Verified 2026-11-21 |
#13 源瑞达 Indication Expanded | Inaticabtagene autoleucel Injection 纳基奥仑赛注射液 Full drug profile → | 合源生物科技股份有限公司 | Expanded in 2026: adult r/r B-ALL plus ≥3L adult r/r LBCL (DLBCL NOS, transformed FL, PMBCL). | Jan 1, 2026 – Dec 31, 2027 Announced · Effective Jan 1, 2027 | NHSA · PDF p.3 Verified 2026-11-21 |
#14 Fucaso / 福可苏 Retained from 2025 | Equecabtagene autoleucel Injection 伊基奥仑赛注射液 | 南京驯鹿生物医药有限公司 | Adult relapsed or refractory multiple myeloma progressing after ≥3 prior lines (including at least one PI and IMiD). | Jan 1, 2026 – Dec 31, 2027 Effective | NHSA · PDF p.3 Verified 2026-11-21 |
#15 赛恺泽 Retained from 2025 | Zevorcabtagene autoleucel Injection 泽沃基奥仑赛注射液 | 恺兴生命科技(上海)有限公司 | Adult relapsed or refractory multiple myeloma progressing after ≥3 prior lines (including at least one PI and IMiD). | Jan 1, 2026 – Dec 31, 2027 Effective | NHSA · PDF p.3 Verified 2026-11-21 |
#16 恺力美 Added 2026 | Satricabtagene autoleucel Injection 舒瑞基奥仑赛注射液 | 恺兴生命科技(上海)有限公司 | CLDN18.2-positive, HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma after ≥2 prior failed lines. | Jan 1, 2027 – Dec 31, 2028 Announced · Effective Jan 1, 2027 | NHSA · PDF p.3 Verified 2026-11-21 |
#17 普利得凯 Added 2026 | Pricabtagene autoleucel Injection 普基奥仑赛注射液 | 重庆精准生物技术有限公司 | CD19-positive refractory or relapsed B-cell acute lymphoblastic leukemia in patients aged 3–21 years. | Jan 1, 2027 – Dec 31, 2028 Announced · Effective Jan 1, 2027 | NHSA · PDF p.3 Verified 2026-11-21 |
#18 Hicara / 恒凯莱 Added 2026 | Ranicabtagene autoleucel Injection 雷尼基奥仑赛注射液 | 上海恒润达生生物科技股份有限公司 | Adult relapsed or refractory LBCL after ≥2 prior lines of systemic therapy (DLBCL NOS, transformed FL, HGBL with MYC/BCL2 rearrangements, HGBL NOS). | Jan 1, 2027 – Dec 31, 2028 Announced · Effective Jan 1, 2027 | NHSA · PDF p.4 Verified 2026-11-21 |
#19 普罗仙安 Retained from 2025 | Para-toluenesulfonamide Injection 甲苯磺酰胺注射液 | 天津红日健达康医药科技有限公司 | Adult central non-small cell lung cancer to relieve severe central airway obstruction. | Jan 1, 2026 – Dec 31, 2027 Effective | NHSA · PDF p.4 Verified 2026-11-21 |
#20 Zepzelca / 赞必佳 Retained from 2025 | Lurbinectedin for Injection 注射用芦比替定 | PharmaMar AG Authorized: 南京绿叶制药有限公司 | Adult metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy. | Jan 1, 2026 – Dec 31, 2027 Effective | NHSA · PDF p.4 Verified 2026-11-21 |
#21 Crysvita / 麟平 Added 2026 | Burosumab Injection 布罗索尤单抗注射液 | Kyowa Kirin Co.,Ltd. Authorized: 维健(中国)制药有限公司 | (1) X-linked hypophosphatemia (XLH) in adults and children ≥1y; (2) FGF23-related hypophosphatemia in adult tumor-induced osteomalacia (TIO). | Jan 1, 2027 – Dec 31, 2028 Announced · Effective Jan 1, 2027 | NHSA · PDF p.4 Verified 2026-11-21 |
#22 Kisunla / 记能达 Retained from 2025 | Donanemab Injection 多奈单抗注射液 | Eli Lilly and Company Authorized: 礼来贸易有限公司 | Mild cognitive impairment (MCI) due to Alzheimer's disease and mild Alzheimer's disease dementia. | Jan 1, 2026 – Dec 31, 2027 Effective | NHSA · PDF p.4 Verified 2026-11-21 |
#23 Leqembi / 乐意保 Retained from 2025 | Lecanemab Injection 仑卡奈单抗注射液 | Eisai Inc. Authorized: 卫材(中国)药业有限公司 | Mild cognitive impairment (MCI) due to Alzheimer's disease and mild Alzheimer's disease dementia. | Jan 1, 2026 – Dec 31, 2027 Effective | NHSA · PDF p.4 Verified 2026-11-21 |
#24 Wainua / 万诺维 Added 2026 | Eplontersen Sodium Injection 依普隆特生钠注射液 Full drug profile → | AstraZeneca AB Authorized: 阿斯利康(无锡)贸易有限公司 | Polyneuropathy of hereditary transthyretin-mediated amyloidosis (ATTRv-PN) in adult patients. | Jan 1, 2027 – Dec 31, 2028 Announced · Effective Jan 1, 2027 | NHSA · PDF p.4 Verified 2026-11-21 |
#25 Qalsody / 凯盛迪 Added 2026 | Tofersen Injection 托夫生注射液 Full drug profile → | Biogen MA Inc. Authorized: 渤健生物科技(上海)有限公司 | Adult amyotrophic lateral sclerosis (ALS) associated with a SOD1 gene mutation. | Jan 1, 2027 – Dec 31, 2028 Announced · Effective Jan 1, 2027 | NHSA · PDF p.4 Verified 2026-11-21 |
#26 — Added 2026 | Diazoxide Oral Suspension 二氮嗪口服混悬液 | 宿州亿帆药业有限公司 | Congenital hyperinsulinemic hypoglycemia. | Jan 1, 2027 – Dec 31, 2028 Announced · Effective Jan 1, 2027 | NHSA · PDF p.4 Verified 2026-11-21 |
#27 SIR-Spheres Added 2026 | Yttrium [90Y] Microspheres Injection 钇[90Y]微球注射液 | Sirtex Medical Pty Ltd Authorized: 武汉远大制药集团销售有限公司 | Unresectable colorectal liver metastases after failure of standard therapy. | Jan 1, 2027 – Dec 31, 2028 Announced · Effective Jan 1, 2027 | NHSA · PDF p.4 Verified 2026-11-21 |
#28 Pluvicto / 派威妥 Added 2026 | Lutetium (177Lu) vipivotide tetraxetan Injection 镥[177Lu]特昔维匹肽注射液 Full drug profile → | Novartis Pharma Schweiz AG Authorized: 诺华医药科技(浙江)有限公司 | Adult PSMA-positive mCRPC post-ARPI (suitable to delay chemotherapy) or post-ARPI and taxane chemotherapy. | Jan 1, 2027 – Dec 31, 2028 Announced · Effective Jan 1, 2027 | NHSA · PDF p.5 Verified 2026-11-21 |
2025 Commercial List Entries Not Carried Into 2026 (3)
Verified by diffing the official 2025 Commercial List PDF (19 drugs) against the 2026 Commercial List PDF (28 drugs). Two therapies graduated directly into the 2026 basic NRDL.
| 2025 No. & Brand | Generic Name | 2026 Outcome | MAH | 2025 Source |
|---|---|---|---|---|
2025 #2 海普益 | Sapropterin dihydrochloride 盐酸沙丙蝶呤片 | Graduated to 2026 Basic NRDL (#42) Reimbursed under basic medical insurance effective Jan 1, 2027. | Shandong New Time Pharmaceutical Co., Ltd. | NHSA · PDF p.2 |
2025 #12 Carteyva / 倍诺达 | Relmacabtagene autoleucel 瑞基奥仑赛注射液 | Graduated to 2026 Basic NRDL (#297) Reimbursed under basic medical insurance effective Jan 1, 2027. | JW Therapeutics (Shanghai) Co., Ltd. | NHSA · PDF p.4 |
2025 #16 Tazverik / 达唯珂 | Tazemetostat hydrobromide 氢溴酸他泽司他片 | Omitted from 2026 Commercial List Not listed in 2026 Commercial List or 2026 NRDL. | Epizyme, Inc. | NHSA · PDF p.4 |